174822-86-7

Usage

Molecular structure

The compound has a complex molecular structure that consists of a piperidine ring attached to a carboxylic acid group and a 2-hydroxyphenyl group with a t-butyl ester.

Ester derivative

It is an ester derivative of 1-piperidinecarboxylic acid and 4-(2-hydroxyphenyl), indicating that it is formed by the reaction of the carboxylic acid group with an alcohol (in this case, the 2-hydroxyphenol group).

Biological activity

The compound has potential biological activities due to its structural features, which may make it useful in the pharmaceutical industry.

Ongoing research

Research and analysis of the properties and potential uses of 1-Piperidinecarboxylic acid, 4-(2-hydroxyphenyl)-, 1,1-dimethylethyl ester are ongoing, indicating that its full range of applications and effects are not yet fully understood.

Upstream product

• 910605-43-5 4-(2-hydroxyphenyl)piperidine hydrobromide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 161609-76-3 4-(2-hydroxyphenyl)-piperidine 
• 58333-75-8 4-(2-methoxyphenyl)piperidine 
• 1269025-34-4 4-(2-hydroxyphenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 1378810-75-3 C₁₁H₁₄NO^(1-)*Na⁽¹⁺⁾ 
• 1048970-17-7 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 910605-27-5 4-[2-(2-chloro-ethoxy)-phenyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1201927-69-6 C₁₈H₂₀FNO 
• 899356-74-2 C₁₇H₁₉NO 
• 1201927-87-8 C₁₇H₁₈ClNO 
• 1201927-81-2 C₁₇H₁₈FNO 
• 1201927-84-5 C₁₇H₁₈FNO 
• 1201927-92-5 C₁₈H₂₀FNO 
• 1201927-68-5 C₁₈H₂₁NO 
• 1201927-75-4 C₁₈H₂₀FNO 
• 951774-81-5 C₂₁H₂₉N₃O₃ 
• 951774-78-0 C₁₈H₂₆BrNO₃ 
• 947614-65-5 C₂₂H₃₄N₂O₃ 
• 910605-44-6 4-[2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 874296-73-8 4-[2-(nonafluorobutane-1-sulfonyloxy)-phenyl]-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS

Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

Design, Synthesis, and Pharmacological Characterization of Heterobivalent Ligands for the Putative 5-HT2A/mGlu2Receptor Complex

We report the synthesis of the first series of heterobivalent ligands targeting the putative heteromeric 5-HT2A/mGlu2 receptor complex, based on the 5-HT2A antagonist MDL-100,907 and the mGlu2 ago-PAM JNJ-42491293. The functional properties of monovalent and heterobivalent ligands were characterized in 5-HT2A-, mGlu2/Gqo5-, 5-HT2A/mGlu2-, and 5-HT2A/mGlu2/Gqo5-expressing HEK293 cells using a Ca2+ imaging assay and a [3H]ketanserin binding assay. Pronounced functional crosstalk was observed between the two receptors in 5-HT2A/mGlu2 and 5-HT2A/mGlu2/Gqo5 cells. While the synthesized monovalent ligands retained the 5-HT2A antagonist and mGlu2 ago-PAM functionalities, the seven bivalent ligands inhibited 5-HT-induced responses in 5-HT2A/mGlu2 cells and both 5-HT- and Glu-induced responses in 5-HT2A/mGlu2/Gqo5 cells. However, no definitive correlation between the functional potency and spacer length of the ligands was observed, an observation substantiated by the binding affinities exhibited by the compounds in 5-HT2A, 5-HT2A/mGlu2, and 5-HT2A/mGlu2/Gqo5 cells. In conclusion, while functional crosstalk between 5-HT2A and mGlu2 was demonstrated, it remains unclear how these heterobivalent ligands interact with the putative receptor complex.

Enantiospecific sp2–sp3 Coupling of ortho- and para-Phenols with Secondary and Tertiary Boronic Esters

The coupling of ortho- and para-phenols with secondary and tertiary boronic esters has been explored. In the case of para-substituted phenols, after reaction of a dilithio phenolate species with a boronic ester, treatment with Ph3BiF2 or Martin's sulfurane gave the coupled product with complete enantiospecificity. The methodology was applied to the synthesis of the broad spectrum antibacterial natural product (?)-4-(1,5-dimethylhex-4-enyl)-2-methyl phenol. For ortho-substituted phenols, initial incorporation of a benzotriazole on the phenol oxygen atom was required. Subsequent ortho-lithiation and borylation gave the coupled product, again with complete stereospecificity.

Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists

Compounds that are both norepinephrine reuptake inhibitors (NRI) and 5-HT1A partial agonists may have the potential to treat neuropsychiatric disorders including attention deficit hyperactivity disorder (ADHD) and depression. Targeted screening

Piperidinyl substituted cyclohexane-1,4-diamines

The present invention relates to piperidine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as α1a/α1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.

2-(1H-INDOLYLSULFANYL) -ARYL AMINE DERIVATIVES FOR USE IN THE TREATMENT OF AFFECTIVE DISORDERS, PAIN, ADHD AND STRESS URINARY INCONTINENCE

The present invention relates to aniline derivatives of the general formula I as the free base or salts thereof and their use.

Serotonin 5-HT1A and dopamin D2 receptor ligands

The present invention relates to a novel series of 4-phenylpiperazines, 4-phenylpiperidines and 4-phenyl-1,2,3,6-tetrahydropyridines compounds of general formula (I) wherein A is alkylene, alkenylene, alkynylene, and C3-7cycloalkylene; R1is a C3-10alkyl, alkenyl, or alkynyl group, cycloalk(en)yl, cycloalk(en)yl-alk(en/yn)yl, trifluoromethylsulfonyl, or alkylsulfonyl, R2-R5are optional substituents; R9and R10are hydrogen, alkyl or together form an ethylene or propylene bridge; W is O or S; V is O, S, CR6R7, or NR8wherein R6, R7, and R8are hydrogen or alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, optionally substituted arylalkyl or aryl, or R6and R7constitute a 3-7 membered spiro ring; Z is —(CH2)m—, m being 2 or 3 or Z is —CH═CH—; X is N, C or CH; show effects on central serotonin 5-HT1Aand dopamine D2receptors. Thus the novel compounds are useful in the treatment of certain psychic and neurologic disorders, in particular psychosis.